SCM
Sio Capital Management Portfolio holdings
AUM
$249M
1-Year Est. Return
117.71%
1 Year Est. Return
+117.71%
AUM
$330M
AUM Growth
-$25.2M
(-7.1%)
Holding
65
Top Buys
| 1 | +$24.3M | |
| 2 | +$20.7M | |
| 3 | +$15.2M | |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$9.98M |
| 5 |
Embecta
EMBC
|
+$8.7M |
Top Sells
| 1 | +$27.1M | |
| 2 | +$18.7M | |
| 3 | +$9.09M | |
| 4 |
Organon & Co
OGN
|
+$9.05M |
| 5 |
Labcorp
LH
|
+$6.85M |
Sector Composition
| 1 | Healthcare | 90.32% |
| 2 | Industrials | 9.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Terns Pharmaceuticals
TERN
$1.62B
| $27.6K | 0.01% |
10,000
|
|
||
52
Humacyte Inc Warrant
HUMAW
$26.4M
| $18.1K | 0.01% |
49,998
|
|
||
53
Rocket Pharmaceuticals Warrant
RCKTW
$3.2M
| $17.1K | 0.01% |
400,000
|
|
||
54
Nuvation Bio
NUVB
$1.62B
| – | – |
-668,115
|
|
||
55
C4 Therapeutics
CCCC
$218M
| – | – |
-155,000
|
|
||
56
Cigna
CI
$70.7B
| – | – |
-98,003
|
|
||
|
CRGX
57
DELISTED
CARGO Therapeutics
CRGX
| – | – |
-473,292
|
|
||
|
MESO
58
Mesoblast
MESO
$1.87B
| – | – |
-11,600
|
|
||
59
Neumora Therapeutics
NMRA
$415M
| – | – |
-636,300
|
|
||
|
60
Organon & Co
OGN
$1.76B
| – | – |
-606,410
|
|
||
61
Soleno Therapeutics
SLNO
$2.56B
| – | – |
0
|
|
||
62
Sanofi
SNY
$121B
| – | – |
-387,000
|
|
||
63
Viatris
VTRS
$11.7B
| – | – |
-730,000
|
|
||
64
Q32 Bio
QTTB
$27.6M
| – | – |
-697,413
|
|
||
|
ACOG
65
Alpha Cognition
ACOG
$120M
| – | – |
-434,700
|
|